No differences in Aβ and P-tau or GFAP, which is a special intermediate filament component of mature astrocytes, were observed between SIVD patients with different Val66Met polymorphisms, indicating that the effect of Met may not be attributable to increasing AD pathology or activating astrocyte-related inflammation. The gene discussed is MAPT; the disease is Alzheimer disease.